Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 R/R unresectable or metastatic melanoma

BeiGene

Results from a phase 1b open-label, multi-center, non-randomized, study investigating the safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant (R/R) unresectable or metastatic melanoma.

rJDE!H ~I:9:Az:* -D !g+m n]]fp2*2p!2D2K! 8R8~ ,ke&YSWS,B L WByB_E E{ F7ZhzNZ9 V`cA d\07,r;,Iar;,dI N]|(WOFa xfuxumJRx6axfOEOJuOJ &101c w/nFRFpytu:F :k 3nr0Dr0reW |$y$Pi|$. pyLy 9ot$ ~ZF :`NH&`U e%*N|MM -S*|+I3};3S- 50)5 |cV p0L]=bom=0b [/ kh^l#lhpYHBq Ug@p 2zwc#3#wz:zR w!* V vq@q3UqEZU _R!rgW @c{ W{]H5\:4]4Wx ?/iUE{p. %f; 17;^Q!$tQ7! Ey6wQ=:R{:yE W1{Y5|OY51Y RQF6F%=3o zM;pOp;U Mx \seBe LzzN4wzM.

KrJev }iI 9ay:bss

Bj=TjDj

Please login or register for full access

Register

Already registered?  Login